Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Anti-cancer drug could be used in treatment for HIV

30 July 2012

By Dr Daniel Grimes

Appeared in BioNews 667

Scientists have discovered that an anti-cancer drug can revive dormant HIV (human immunodeficiency virus), thereby allowing therapies to act upon the low level inactive virus particles that hide in patients' immune cells and have, until now, been unsusceptible to treatment.

The study, performed by researchers from the University of North Carolina at Chapel Hill, USA, and published in the journal Nature, shows that a single treatment with the drug – called vorinostat – can specifically target dormant virus particles, those which are normally unaffected by standard anti-retroviral therapy.

The current treatment for HIV infection is a cocktail of drugs that suppress HIV replication. However, latent virus particles that aren't replicating evade these therapies by lying dormant in patients' own cells.

During the study, vorinostat, which is normally used to treat lymphoma, was given to eight HIV-positive patients who were already undergoing anti-retroviral therapy. The patients showed an average 4.8-fold increase in viral RNA expression in the cells where dormant HIV is known to hide, a tell-tale sign that the drug had induced the latent HIV to become active. In essence, the drug had forced dormant virus out of its hiding place.

By directly attacking latent HIV infection, this study is another step on the road towards a cure. Dr David Margolis, lead author on the study, said in a press release, 'this research provides new hope for a strategy to eradicate HIV completely from the body'. Steven Deeks, of the University of California, wrote in a Nature Commentary accompanying the main paper, '[this work] is a proof-of-concept study that provides the first evidence that such a cure might be one day feasible'.

To date, Timothy Ray-Brown, the so-called 'Berlin patient', is widely recognised as the only man to have been cured of HIV infection. Brown, who was also suffering from leukaemia, underwent stem cell replacement therapy for his cancer. His doctor was able to find a donor who was naturally resistant to HIV. Thus, the therapy effectively replaced Brown's susceptible cells with resistant cells from the donor. This method cured Brown of HIV infection, and supplied a proof-of-principle that stem cell replacement might be a legitimate pursuit in the fight against HIV.

On the back of this success it was announced this week at the nineteenth International AIDS (acquired immunodeficiency syndrome) conference in Washington DC that two more men receiving stem cell transplants for lymphoma have been effectively cured. One patient is HIV-free after two years, while the second has no detectable HIV DNA in their immune cells three-and-a-half years on. This time, however, the donor cells used were not naturally HIV resistant.

The key seems to have been keeping the patients on anti-retroviral drugs throughout their chemotherapy and transplant. The study was overseen by Dr Daniel Kuritzkes of Brigham and Women's Hospital in Boston, USA. 'We found that immediately before the transplant and after the transplant, HIV DNA was in the cells. As the patients' cells were replaced by the donor cells, the HIV DNA disappeared', Dr Kuritzkes told WITN. In essence, the donor cells replaced the infected cells while the anti-retroviral drugs protected the donor cells from becoming infected themselves.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

10 March 2014 - by Dr Lanay Griessner 
A potential HIV therapy where patients have their blood cells genetically modified to help them resist the virus is safe and promising as a treatment, say researchers after a small clinical trial...
28 January 2013 - by Matthew Thomas 
Altering the genetic makeup of immune cells could provide them with resistance to HIV...

02 July 2012 - by Dr Linda Wijlaars 
A gene that codes for nicotine antibodies has been successful in immunising mice against the drug's effects. But although the treatment appears to work in mice, any 'smoking vaccine' is still a long way off...
11 June 2012 - by Catherine Murphy 
As the UK's largest HIV charity, Terrence Higgins Trust warmly welcomes the decision by the National Institute for Health and Clinical Excellence (NICE) last month to consult on an updated version of its fertility guideline. The new approach outlined by NICE holds the potential to transform fertility services for men and women living with or affected by HIV in the UK who want to become parents...
08 May 2012 - by Helen Brooks 
HIV patients treated over a decade ago with genetically modified immune cells have suffered no serious side effects from the treatment. Although the cells may not have been successful in targeting and killing HIV-infected cells, the results are promising as they bolster the safety credentials of gene therapy for clinical use...
05 December 2011 - by Dr Tamara Hirsch 
US scientists have induced long-lasting HIV protection in mice from a single injection. Their study, published in the journal Nature, uses gene therapy to stimulate production of antibodies against the virus...
04 July 2011 - by Mehmet Fidanboylu 
New research has revealed that a group of generic anti-HIV drugs may be linked to premature ageing. The study, which was carried out by UK scientists at the Institute of Genetic Medicine at Newcastle University, could explain why people treated with this class of drugs sometimes show signs of age-related conditions, such as heart disease and dementia....

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation